73 related articles for article (PubMed ID: 18183572)
1. Repositioning of ETO gene in cells treated with VP-16, an inhibitor of DNA-topoisomerase II.
Rubtsov MA; Terekhov SM; Razin SV; Iarovaia OV
J Cell Biochem; 2008 May; 104(2):692-9. PubMed ID: 18183572
[TBL] [Abstract][Full Text] [Related]
2. Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO.
Fliegauf M; Stock M; Berg T; Lübbert M
Oncogene; 2004 Dec; 23(56):9070-81. PubMed ID: 15489901
[TBL] [Abstract][Full Text] [Related]
3. Leukemogenic AML1-ETO fusion protein increases carcinogen-DNA adduct formation with upregulated expression of cytochrome P450-1A1 gene.
Xu M; Li D; Lu Y; Chen GQ
Exp Hematol; 2007 Aug; 35(8):1249-55. PubMed ID: 17560011
[TBL] [Abstract][Full Text] [Related]
4. The role of topoisomerase II beta on breakage and proximity of RUNX1 to partner alleles RUNX1T1 and EVI1.
Smith KA; Cowell IG; Zhang Y; Sondka Z; Austin CA
Genes Chromosomes Cancer; 2014 Feb; 53(2):117-28. PubMed ID: 24327541
[TBL] [Abstract][Full Text] [Related]
5. Chromatin structural elements and chromosomal translocations in leukemia.
Zhang Y; Rowley JD
DNA Repair (Amst); 2006 Sep; 5(9-10):1282-97. PubMed ID: 16893685
[TBL] [Abstract][Full Text] [Related]
6. Inability of RUNX1/AML1 to breach AML1-ETO block of embryonic stem cell definitive hematopoiesis.
Peterson LF; Lo MC; Okumura AJ; Zhang DE
Blood Cells Mol Dis; 2007; 39(3):321-8. PubMed ID: 17692541
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein.
Fazi F; Racanicchi S; Zardo G; Starnes LM; Mancini M; Travaglini L; Diverio D; Ammatuna E; Cimino G; Lo-Coco F; Grignani F; Nervi C
Cancer Cell; 2007 Nov; 12(5):457-66. PubMed ID: 17996649
[TBL] [Abstract][Full Text] [Related]
8. AML1/ETO-induced survivin expression inhibits transcriptional regulation of myeloid differentiation.
Balkhi MY; Christopeit M; Chen Y; Geletu M; Behre G
Exp Hematol; 2008 Nov; 36(11):1449-60. PubMed ID: 18687517
[TBL] [Abstract][Full Text] [Related]
9. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M
Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359
[TBL] [Abstract][Full Text] [Related]
10. A novel four-way t(6;16;21;8)(p21.3;p11.2;q22;q22) in acute myeloid leukemia with RUNX1/RUNX1T1 rearrangement.
Park KJ; Park HD; Kim HJ; Yoo KH; Koo HH; Kim SH
Cancer Genet Cytogenet; 2009 Jul; 192(2):90-2. PubMed ID: 19596262
[No Abstract] [Full Text] [Related]
11. Chemotherapy-related secondary leukemias: A role for DNA repair by error-prone non-homologous end joining in topoisomerase II - Induced chromosomal rearrangements.
Kantidze OL; Razin SV
Gene; 2007 Apr; 391(1-2):76-9. PubMed ID: 17234368
[TBL] [Abstract][Full Text] [Related]
12. Translocation (8;21)(q22;q22) without rearrangement of RUNX1 and RUNX1T1 genes in a patient with refractory anemia with excess of blasts.
Aguilar A; Talavera M; Villalon C; Garcia-Sagredo JM; de Leon A; Sordo T; Cabello P; Gonzalez FA; Garcia-Galloway E; San Roman C; Ferro T
Cancer Genet Cytogenet; 2008 Jan; 180(1):85-6. PubMed ID: 18068542
[No Abstract] [Full Text] [Related]
13. Identification of a potential "hotspot" DNA region in the RUNX1 gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation.
Ottone T; Hasan SK; Montefusco E; Curzi P; Mays AN; Chessa L; Ferrari A; Conte E; Noguera NI; Lavorgna S; Ammatuna E; Divona M; Bovetti K; Amadori S; Grimwade D; Lo-Coco F
Genes Chromosomes Cancer; 2009 Mar; 48(3):213-21. PubMed ID: 19023877
[TBL] [Abstract][Full Text] [Related]
14. Molecular cytogenetic findings in a three-way novel variant of t(1;8;21)(p35;q22;q22): a unique relocation of the AML1/ETO fusion gene 1p35 in AML-M2.
Ahmad F; Kokate P; Chheda P; Dalvi R; Das BR; Mandava S
Cancer Genet Cytogenet; 2008 Jan; 180(2):153-7. PubMed ID: 18206543
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein.
Yang G; Thompson MA; Brandt SJ; Hiebert SW
Oncogene; 2007 Jan; 26(1):91-101. PubMed ID: 16799637
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of DNA topoisomerase II with etoposide induces association of DNA topoisomerase II alpha, DNA topoisomerase II beta, and nucleolin with BCR 2 of the ETO gene.
Rubtsov MA; Razin SV; Iarovaia OV
Dokl Biochem Biophys; 2008; 423():334-6. PubMed ID: 19230382
[No Abstract] [Full Text] [Related]
17. [Topoisomerase II inhibitors etoposide and doxorubicin induced rearrangement and fusion of AML1 gene].
Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2003 Dec; 24(12):621-3. PubMed ID: 14761607
[TBL] [Abstract][Full Text] [Related]
18. Duplication and triplication of der(21)t(8;21)(q22;q22) in acute myeloid leukemia.
Mikulasovich M; LeBlanc A; Scalise A; Manwani D; Keyzner A; Najfeld V
Cancer Genet Cytogenet; 2009 Jan; 188(2):83-7. PubMed ID: 19100510
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the topoisomerase II-DNA cleavable complex by the ortho-quinone derivative of the antitumor drug etoposide (VP-16).
Gantchev TG; Hunting DJ
Biochem Biophys Res Commun; 1997 Aug; 237(1):24-7. PubMed ID: 9266822
[TBL] [Abstract][Full Text] [Related]
20. Genotoxicity of etoposide: greater susceptibility of MLL than other target genes.
Ng A; Taylor GM; Eden OB
Cancer Genet Cytogenet; 2006 Jan; 164(2):164-7. PubMed ID: 16434323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
